Physiologic Hyperbilirubinemia in the Neonatal Period

Odell, Gerard B.

doi:10.1056/nejm196707272770406

Cited by 37 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many factors, both prenatal and postnatal have been reported to play a part in the aetiology of physiological jaundice of the newborn (Wood et al, 1962;Odell, 1967). We report the influence which two types of "steroid therapy" appear to have on bilirubin concentrations in the newborn.…”

Section: Discussionmentioning

confidence: 87%

Effect on Neonatal Jaundice of Oestrogens and Progestogens Taken before and after Conception

McConnell¹,

Glasgow²,

McNair³

1973

BMJ

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 87%

Effect on Neonatal Jaundice of Oestrogens and Progestogens Taken before and after Conception

McConnell¹,

Glasgow²,

McNair³

1973

BMJ

View full text Add to dashboard Cite

“…In the normal infants (maximum serum bilirubin, 8 mg/100 ml), the primary binding sites for bilirubin on albumin would not be saturated (55). Our calculations of bilirubin turnover do not consider the possibility of an enterohepatic circulation of bilirubin in the newborn (56). If such a circulation contributes significantly to the bilirubin load, the ability of the newborn to excrete bilirubin must be even greater than our calculations imply.…”

Section: Co Production and Mean Red Cell Life Span (Mls)mentioning

confidence: 82%

Endogenous production of carbon monoxide in normal and erythroblastotic newborn infants

Maisels¹,

Pathak²,

Nelson³

et al. 1971

J. Clin. Invest.

128

View full text Add to dashboard Cite

A B S T R A C T The endogenous production of carbon monoxide (Vco) in newborn infants was measured by serial determinations of blood carboxyhemoglobin during rebreathing in a closed system. Mean Vco in nine full-term infants was 13.7 zt3.6 Al CO/kg per hr (SD), and in four erythroblastotic infants Vco ranged from 37 to 154 sl CO/kg per hr preceding exchange transfusion. Mean red cell life-span (MLS) and total bilirubin production were calculated from Yco. MLS in normal newborns was 88 :1:15 days (SD), and bilirubin production was 8.5 =12.3 mg/kg per 24 hr. This is more than twice the amount of bilirubin normally produced in the adult per kilogram of body weight. Normal infants achieved a net excretion of bilirubin of at least 5.6 4-2.3 mg/kg per 24 hr (SD) as calculated from the bilirubin production and the measured rise in serum bilirubin concentration.The measurement of Vco should prove valuable in the study of red blood cell survival and bilirubin metabolism in the newborn infant. INTRODUCTIONThe recent studies of Coburn and coworkers (1-3) have confirmed the original observations by Sjbstrand (4-6) that carbon monoxide (CO) is endogenously produced in normal man, and that approximately 1 mole of CO is produced per mole of heme catabolized (2).

show abstract

“…This maintains a level of CYP3A protein expression, but function may vary as CYP3A4 and CYP3A7 exhibit different substrate specificities, catalytic efficiency and, consequently, metabolic capacity 51. UGT has only 1% of adult activity at birth52 before rapidly increasing to adult levels by 14 weeks 53. Decreased glucuronidation of chloramphenicol in newborn infants is believed to be a factor in the susceptibility of babies to Grey Baby syndrome 54 55…”

Section: Paediatric-specific Issues and Pharmacogenomicsmentioning

confidence: 99%

Paediatric pharmacogenomics: an overview

Hawcutt

Thompson

Smyth³

et al. 2012

Archives of Disease in Childhood

View full text Add to dashboard Cite

Pharmacogenomics research is becoming more prevalent in both academia and the pharmaceutical industry. While some discoveries have been integrated into practice and are benefiting patient care, these successes have been limited given the vast amount of research undertaken. However, the advances in high-throughput genomic technologies, better study designs and improved understanding of complexity, means that pharmacogenomic determinants of drug response will continue to be identified. It is important to develop an understanding of the basis of pharmacogenomics in clinical teams to allow accurate interpretation of the findings, and facilitate their implementation into clinical care (if appropriate). This article explains the science behind pharmacogenomics, and describes some of the challenges that have been encountered in the field, with a specific focus on paediatrics.

show abstract

Physiologic Hyperbilirubinemia in the Neonatal Period

Cited by 37 publications

References 18 publications

Effect on Neonatal Jaundice of Oestrogens and Progestogens Taken before and after Conception

Effect on Neonatal Jaundice of Oestrogens and Progestogens Taken before and after Conception

Endogenous production of carbon monoxide in normal and erythroblastotic newborn infants

Paediatric pharmacogenomics: an overview

Contact Info

Product

Resources

About